Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 19/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | LHCGR | P22888 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | LGR4 | Q9BXB1 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.68 |
| ▸ | TSPO | P30536 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.68 |
| ▸ | CCKBR | P32239 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26698817 | 1.00 | RXFP1 (1.00) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL24515623 | 1.00 | RXFP1 (1.00) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25646985 | 1.00 | RXFP1 (1.00) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25642962 | 1.00 | RXFP1 (1.00) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL26613198 | 1.00 | RXFP1 (1.00) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25642461 | 0.92 | RXFP1 (0.85) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25642789 | 0.90 | RXFP1 (0.82) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25642690 | 0.90 | RXFP1 (0.81) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL26723899 | 0.89 | RXFP1 (0.80) | RXFP1ABCB11LHCGRSCN5ALGR4 | |
| SCHEMBL25642994 | 0.88 | RXFP1 (0.91) | RXFP1ABCB11LHCGRSCN5ALGR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | RXFP1 1/4885ABCB11 1382/4885LHCGR 1872/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | RXFP1 1/4885ABCB11 1382/4885LHCGR 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.